Rethinking eligibility creep.
Maryanne
M
Kazanis
Craig
C
Leonardi
Ken
K
Gordon
Bruce
B
Strober
Alan
A
Menter
Alexa B
AB
Kimball
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018849:Controlled Clinical Trials as Topic; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D018579:Patient Selection; D015990:Placebo Effect; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068879:Adalimumab